A Randomized Phase 3 Study of Antineoplastons A10 and AS2-1 vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy

Trial Profile

A Randomized Phase 3 Study of Antineoplastons A10 and AS2-1 vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Sep 2013 Planned end date changed from 1 Dec 2015 to 1 Dec 2018 as reported by ClinicalTrials.gov.
    • 16 Sep 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top